SUBSCRIBE
SUBSCRIBE
News   Drug Development

Introgen Therapeutics, Inc.'s Flagship Cancer Drug Advexin Questioned

July 15, 2008 | 
1 min read

Introgen Therapeutics Inc. saw its stock price plummet about 20 percent Monday, the same day a report from TheStreet.com was published questioning the effectiveness of the company’s much-touted cancer drug Advexin.

Clinical research Phase I Phase II
MORE ON THIS TOPIC
Business consultant. Hands help a businessman is falling from a graph vector
Neuropsychiatric disorders
Biohaven Disappoints Again, This Time in Phase II/III Bipolar Mania Trial
March 4, 2025
 · 
2 min read
 · 
Tristan Manalac
Deviation from the plan, path or norms. Choosing an alternative way, changing the plans and flexibility.
Depression
Neumora Shakes Up Phase III MDD Trials After January Miss
March 3, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Glitter Vibrant Spheres Abstract Background Digital Renderingv
Phase III
Takeda-Protagonist Drug for Incurable Cancer Reduces Need for Blood Withdrawals in Phase III Trial
March 3, 2025
 · 
2 min read
 · 
Annalee Armstrong
Pop art Medicine pill or tablet icon isolated on color background. Capsule pill and drug sign. Pharmacy design. Vector Illustration
Pain
Lexicon to Advance Non-Opioid Painkiller Despite Mid-Stage Trial Failure
March 3, 2025
 · 
2 min read
 · 
Dan Samorodnitsky